Effects of CB-VEGF-A injection in rat flap models for improved survival

Minekatsu Akimoto, Akira Takeda, Osamu Matsushita, Joe Inoue, Keiko Sakamoto, Masakazu Hattori, Natsuko Kounoike, Eiju Uchinuma

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Various carriers have been tested as drug delivery systems in an attempt to sustain the action of growth factors. Gene therapy has also been adopted to achieve lasting effects but without satisfactory results. Because the authors believe that the angiogenic effect of vascular endothelial growth factor (VEGF) can be enhanced by anchoring the fusion protein composed of the Clostridium-derived collagen-binding domain and recombinant VEGF-A164 (CB-VEGF-A) in the tissue, they examined the changes in blood flow of random pattern flaps following treatment of the dorsal region of the rat with the fusion proteins before skin flap elevation. Methods: The authors administered CB-VEGF-A subcutaneously into the dorsal region of Sprague-Dawley rats 7 days before creation of skin flaps, and compared the necrosis rate observed on the seventh day after flap elevation with that of vehicle controls. The authors also performed comparison with a group treated by subcutaneous administration of non-collagen-binding domain-binding VEGF. The skin flaps were also examined histologically. Results: The flap necrosis rate was lower in the CB-VEGF-A group (36.7 ± 7.4 percent) than in the control group (48.2 ± 5.4 percent). However, no improvement was observed in the non-collagen-binding domain-binding VEGF group. Moreover, histologic examination revealed an increase in the subcutaneous blood vessel counts. Conclusion: CB-VEGF-A has an angiogenic effect on rat dorsal skin flaps and improves flap survival.

Original languageEnglish
Pages (from-to)717-725
Number of pages9
JournalPlastic and Reconstructive Surgery
Volume131
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Vascular Endothelial Growth Factor A
Collagen
Injections
Skin
Necrosis
Clostridium
Drug Delivery Systems
Genetic Therapy
Blood Vessels
Sprague Dawley Rats
Intercellular Signaling Peptides and Proteins
Proteins
Control Groups

ASJC Scopus subject areas

  • Surgery

Cite this

Effects of CB-VEGF-A injection in rat flap models for improved survival. / Akimoto, Minekatsu; Takeda, Akira; Matsushita, Osamu; Inoue, Joe; Sakamoto, Keiko; Hattori, Masakazu; Kounoike, Natsuko; Uchinuma, Eiju.

In: Plastic and Reconstructive Surgery, Vol. 131, No. 4, 04.2013, p. 717-725.

Research output: Contribution to journalArticle

Akimoto, M, Takeda, A, Matsushita, O, Inoue, J, Sakamoto, K, Hattori, M, Kounoike, N & Uchinuma, E 2013, 'Effects of CB-VEGF-A injection in rat flap models for improved survival', Plastic and Reconstructive Surgery, vol. 131, no. 4, pp. 717-725. https://doi.org/10.1097/PRS.0b013e3182818b34
Akimoto, Minekatsu ; Takeda, Akira ; Matsushita, Osamu ; Inoue, Joe ; Sakamoto, Keiko ; Hattori, Masakazu ; Kounoike, Natsuko ; Uchinuma, Eiju. / Effects of CB-VEGF-A injection in rat flap models for improved survival. In: Plastic and Reconstructive Surgery. 2013 ; Vol. 131, No. 4. pp. 717-725.
@article{bd58e73060634f369bfc8642e79da3e5,
title = "Effects of CB-VEGF-A injection in rat flap models for improved survival",
abstract = "Background: Various carriers have been tested as drug delivery systems in an attempt to sustain the action of growth factors. Gene therapy has also been adopted to achieve lasting effects but without satisfactory results. Because the authors believe that the angiogenic effect of vascular endothelial growth factor (VEGF) can be enhanced by anchoring the fusion protein composed of the Clostridium-derived collagen-binding domain and recombinant VEGF-A164 (CB-VEGF-A) in the tissue, they examined the changes in blood flow of random pattern flaps following treatment of the dorsal region of the rat with the fusion proteins before skin flap elevation. Methods: The authors administered CB-VEGF-A subcutaneously into the dorsal region of Sprague-Dawley rats 7 days before creation of skin flaps, and compared the necrosis rate observed on the seventh day after flap elevation with that of vehicle controls. The authors also performed comparison with a group treated by subcutaneous administration of non-collagen-binding domain-binding VEGF. The skin flaps were also examined histologically. Results: The flap necrosis rate was lower in the CB-VEGF-A group (36.7 ± 7.4 percent) than in the control group (48.2 ± 5.4 percent). However, no improvement was observed in the non-collagen-binding domain-binding VEGF group. Moreover, histologic examination revealed an increase in the subcutaneous blood vessel counts. Conclusion: CB-VEGF-A has an angiogenic effect on rat dorsal skin flaps and improves flap survival.",
author = "Minekatsu Akimoto and Akira Takeda and Osamu Matsushita and Joe Inoue and Keiko Sakamoto and Masakazu Hattori and Natsuko Kounoike and Eiju Uchinuma",
year = "2013",
month = "4",
doi = "10.1097/PRS.0b013e3182818b34",
language = "English",
volume = "131",
pages = "717--725",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effects of CB-VEGF-A injection in rat flap models for improved survival

AU - Akimoto, Minekatsu

AU - Takeda, Akira

AU - Matsushita, Osamu

AU - Inoue, Joe

AU - Sakamoto, Keiko

AU - Hattori, Masakazu

AU - Kounoike, Natsuko

AU - Uchinuma, Eiju

PY - 2013/4

Y1 - 2013/4

N2 - Background: Various carriers have been tested as drug delivery systems in an attempt to sustain the action of growth factors. Gene therapy has also been adopted to achieve lasting effects but without satisfactory results. Because the authors believe that the angiogenic effect of vascular endothelial growth factor (VEGF) can be enhanced by anchoring the fusion protein composed of the Clostridium-derived collagen-binding domain and recombinant VEGF-A164 (CB-VEGF-A) in the tissue, they examined the changes in blood flow of random pattern flaps following treatment of the dorsal region of the rat with the fusion proteins before skin flap elevation. Methods: The authors administered CB-VEGF-A subcutaneously into the dorsal region of Sprague-Dawley rats 7 days before creation of skin flaps, and compared the necrosis rate observed on the seventh day after flap elevation with that of vehicle controls. The authors also performed comparison with a group treated by subcutaneous administration of non-collagen-binding domain-binding VEGF. The skin flaps were also examined histologically. Results: The flap necrosis rate was lower in the CB-VEGF-A group (36.7 ± 7.4 percent) than in the control group (48.2 ± 5.4 percent). However, no improvement was observed in the non-collagen-binding domain-binding VEGF group. Moreover, histologic examination revealed an increase in the subcutaneous blood vessel counts. Conclusion: CB-VEGF-A has an angiogenic effect on rat dorsal skin flaps and improves flap survival.

AB - Background: Various carriers have been tested as drug delivery systems in an attempt to sustain the action of growth factors. Gene therapy has also been adopted to achieve lasting effects but without satisfactory results. Because the authors believe that the angiogenic effect of vascular endothelial growth factor (VEGF) can be enhanced by anchoring the fusion protein composed of the Clostridium-derived collagen-binding domain and recombinant VEGF-A164 (CB-VEGF-A) in the tissue, they examined the changes in blood flow of random pattern flaps following treatment of the dorsal region of the rat with the fusion proteins before skin flap elevation. Methods: The authors administered CB-VEGF-A subcutaneously into the dorsal region of Sprague-Dawley rats 7 days before creation of skin flaps, and compared the necrosis rate observed on the seventh day after flap elevation with that of vehicle controls. The authors also performed comparison with a group treated by subcutaneous administration of non-collagen-binding domain-binding VEGF. The skin flaps were also examined histologically. Results: The flap necrosis rate was lower in the CB-VEGF-A group (36.7 ± 7.4 percent) than in the control group (48.2 ± 5.4 percent). However, no improvement was observed in the non-collagen-binding domain-binding VEGF group. Moreover, histologic examination revealed an increase in the subcutaneous blood vessel counts. Conclusion: CB-VEGF-A has an angiogenic effect on rat dorsal skin flaps and improves flap survival.

UR - http://www.scopus.com/inward/record.url?scp=84878104629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878104629&partnerID=8YFLogxK

U2 - 10.1097/PRS.0b013e3182818b34

DO - 10.1097/PRS.0b013e3182818b34

M3 - Article

VL - 131

SP - 717

EP - 725

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 4

ER -